BMI and Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Study and Meta-Analysis

Carmichael, 2004, Obesity and breast cancer: a review of the literature, Breast, 13, 85, 10.1016/j.breast.2003.03.001 Haslam, 2005, Obesity, Lancet, 366, 1197, 10.1016/S0140-6736(05)67483-1 Xia, 2014, Body mass index and risk of breast cancer: a nonlinear dose-response meta-analysis of prospective studies, Sci Rep, 4, 7480, 10.1038/srep07480 1997, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer, Lancet, 350, 1047, 10.1016/S0140-6736(97)08233-0 Borugian, 2003, Waist-to-hip ratio and breast cancer mortality, Am J Epidemiol, 158, 963, 10.1093/aje/kwg236 Caan, 2008, Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer, Cancer Causes Control, 19, 1319, 10.1007/s10552-008-9203-0 Dawood, 2008, Prognostic value of body mass index in locally advanced breast cancer, Clin Cancer Res, 14, 1718, 10.1158/1078-0432.CCR-07-1479 Kroenke, 2005, Weight, weight gain, and survival after breast cancer diagnosis, J Clin Oncol, 23, 1370, 10.1200/JCO.2005.01.079 Tartter, 1981, Cholesterol and obesity as prognostic factors in breast cancer, Cancer, 47, 2222, 10.1002/1097-0142(19810501)47:9<2222::AID-CNCR2820470919>3.0.CO;2-5 Protani, 2010, Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis, Breast Cancer Res Treat, 123, 627, 10.1007/s10549-010-0990-0 Carmichael, 2006, Obesity and prognosis of breast cancer, Obes Rev, 7, 333, 10.1111/j.1467-789X.2006.00261.x Chen, 2012, Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer, PLoS One, 7, e41380, 10.1371/journal.pone.0041380 Ewertz, 2011, Effect of obesity on prognosis after early-stage breast cancer, J Clin Oncol, 29, 25, 10.1200/JCO.2010.29.7614 Litton, 2008, Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer, J Clin Oncol, 26, 4072, 10.1200/JCO.2007.14.4527 Nahleh, 2011, Breast cancer, obesity and hormonal imbalance: a worrisome trend, Expert Rev Anticancer Ther, 11, 817, 10.1586/era.11.67 Dignam, 2003, Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer, J Natl Cancer Inst, 95, 1467, 10.1093/jnci/djg060 Gianni, 2009, Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer, J Clin Oncol, 27, 2474, 10.1200/JCO.2008.19.2567 Kuerer, 1999, Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy, J Clin Oncol, 17, 460, 10.1200/JCO.1999.17.2.460 Mano, 2004, Primary chemotherapy for breast cancer: the evidence and the future, Ann Oncol, 15, 1161, 10.1093/annonc/mdh302 Rastogi, 2008, Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27, J Clin Oncol, 26, 778, 10.1200/JCO.2007.15.0235 Untch, 2011, Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups, J Clin Oncol, 29, 3351, 10.1200/JCO.2010.31.4930 von Minckwitz, 2012, Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol, 30, 1796, 10.1200/JCO.2011.38.8595 Eralp, 2009, Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger, J Cancer Res Clin Oncol, 135, 141, 10.1007/s00432-008-0428-9 Lee, 2012, Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data, J Breast Cancer, 15, 427, 10.4048/jbc.2012.15.4.427 Leitlinienprogramm Onkologie der AWMF DKeVuDKeV. Interdisciplinary S3 guideline for diagnostic, therapy and follow-up in breast carcinoma. 2012. Available at: http://www.awmf.org/uploads/tx_szleitlinien/032-045OL_k_S3_Brustkrebs_Mammakarzinom_Diagnostik_Therapie_Nachsorge_2012-07.pdf. Accessed: July 2, 2012. World Health Organization. BMI classification. Global Database on Body Mass Index. 2006. Available at: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed: March 24, 2016. 1982, The World Health Organization Histological Typing of Breast Tumors–Second Edition. The World Health Organization, Am J Clin Pathol, 78, 806, 10.1093/ajcp/78.6.806 Guarneri, 2006, Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors, J Clin Oncol, 24, 1037, 10.1200/JCO.2005.02.6914 Hennessy, 2005, Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy, J Clin Oncol, 23, 9304, 10.1200/JCO.2005.02.5023 Mazouni, 2007, Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome, J Clin Oncol, 25, 2650, 10.1200/JCO.2006.08.2271 Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med, 6, e1000100, 10.1371/journal.pmed.1000100 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, e1000097, 10.1371/journal.pmed.1000097 Schwarzer, 2007, “meta: An R package for Meta-Analysis”, R News, 7, 40 DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 Arce-Salinas, 2014, Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients, Breast Cancer Res Treat, 146, 183, 10.1007/s10549-014-2977-8 Del Fabbro, 2012, The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer, Oncologist, 17, 1240, 10.1634/theoncologist.2012-0169 Iwase, 2014, The effect of molecular subtype and body mass index on neo-adjuvant chemotherapy in breast cancer patients, Breast, 23, 264, 10.1016/j.breast.2013.11.008 Bossuyt, 2015, Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration, Ann Oncol, 26, 1280, 10.1093/annonc/mdv161 Rakha, 2012, The prognostic significance of lymphovascular invasion in invasive breast carcinoma, Cancer, 118, 3670, 10.1002/cncr.26711 Fontanella, 2015, Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials, Breast Cancer Res Treat, 150, 127, 10.1007/s10549-015-3287-5 Baselga, 2012, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial, Lancet, 379, 633, 10.1016/S0140-6736(11)61847-3 Pernas Simon, 2014, Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications, Ther Adv Med Oncol, 6, 210, 10.1177/1758834014535650 Houssami, 2012, Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy, Eur J Cancer, 48, 3342, 10.1016/j.ejca.2012.05.023 Cortazar, 2014, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, 384, 164, 10.1016/S0140-6736(13)62422-8 Piccart-Gebhart, 2016, Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial, J Clin Oncol, 34, 1034, 10.1200/JCO.2015.62.1797 von Minckwitz, 2011, Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials, Breast Cancer Res Treat, 125, 145, 10.1007/s10549-010-1228-x